Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Related Party Agreements (Details Textual)

Note 4 - Related Party Agreements (Details Textual) - USD ($)		1 Months Ended			3 Months Ended		9 Months Ended
	Mar. 09, 2017	Jan. 31, 2024	Jan. 31, 2023	Feb. 28, 2015	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2022	Nov. 08, 2022
Fortress [Member]
Percentage of Fully-diluted Outstanding Equity				2.50%
Percentage of Equity or Debt Fnancing				2.50%
Annual Equity Fee Expense					$ 0	$ 0	$ 0	$ 0
Financing Equity Fee					14,000	100,000	200,000	200,000
Fortress [Member] \| Avenue Baergic Founders Agreement [Member]
Excess in Net Assets Value	$ 100,000,000
Fortress [Member] \| Management Services Agreement [Member]
Costs and Expenses					$ 100,000	$ 100,000	$ 400,000	$ 400,000
Fortress [Member] \| The 2023 Annual Equity Fee [Member]
Stock Issued During Period, Shares, New Issues (in shares)		22,476
Fortress [Member] \| The 2022 Annual Equity Fee [Member]
Stock Issued During Period, Shares, New Issues (in shares)			3,085
Fortress [Member] \| Financing Equity Fee [Member]
Stock Issued During Period, Shares, New Issues (in shares)						5,579	31,110	7,491
Stock Issuable, Shares, New Issuance (in shares)					4,023
Fortress [Member] \| Research and Development Expense [Member] \| Management Services Agreement [Member]
Service Provided, Expense Recorded, Percentage				50.00%
Fortress [Member] \| General and Administrative Expense [Member] \| Management Services Agreement [Member]
Service Provided, Expense Recorded, Percentage				50.00%
BaergicBio, Inc.[Member] \| Avenue Baergic Founders Agreement [Member]
Percentage of Equity Fee										2.50%
Percentage Of Additional Consideration Of Equity Fee									2.50%
Percentage Considered For The Calculation Of One-Time Fee									4.50%
Term of Agreement (Year)	5 years
Annual Consulting Fee	$ 500,000
Increase in Annual Consulting Fee	$ 1,000,000